Contribution of Active and Inactive States of the Human 5-HT_<4d> Receptor to the Functional Activities of 5-HT_4-Receptor Agonists
スポンサーリンク
概要
- 論文の詳細を見る
In the present study, binding affinities of 5-hydroxytryptamine-4 (5-HT4) ligands for the human 5-HT4d receptor were determined using the agonist [3H]5-HT and the selective 5-HT4 antagonist [3H]GR113,808. We also compared the affinity differences between [3H]5-HT binding (KH) and [3H]GR113,808 binding (KL) with their activities as 5-HT4 ligands. Binding studies using [3H]5-HT revealed that the human 5-HT4d receptor has two binding sites, whereas [3H]GR113,808 yielded a single binding site. Additionally, the number of [3H]5-HT binding sites decreased in the presence of guanosine-5-O-(3-thiotriphosphate) (GTPγS), but the number of [3H]GR113,808 sites did not change. In competitive binding assays, full agonists such as 5-methoxytryptamine and tegaserod showed 2- to 8-fold higher affinities for [3H]5-HT binding (KH) than for [3H]GR113,808 binding (KL) (KH<KL). Conversely, antagonists showed lower affinities for [3H]5-HT binding than for [3H]GR113,808 binding (KH>KL). Finally, partial agonists displayed similar binding affinities for both radioligands (KH = KL). These findings suggest that the equilibrium between active and inactive states of the human 5-HT4d receptor relies on the functional activities of 5-HT4 ligands, and these states affect the affinities of 5-HT4 ligands in the competitive binding assay.
- 社団法人 日本薬理学会の論文
- 2008-07-20
著者
-
Ohmi Takashi
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Ohmi Takashi
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
EDA Hiroyuki
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
MIKAMI Tadayoshi
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan Inc.
-
SUGIMOTO Hiromi
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan Inc.
-
NAGANEO Rie
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan Inc.
-
SAITO Toshiyuki
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan Inc.
-
Naganeo Rie
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Mikami Tadayoshi
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Eda Hiroyuki
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Sugimoto Hiromi
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Saito Toshiyuki
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
SAITO Toshiyuki
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan Inc.
-
MIKAMI Tadayoshi
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan Inc.
-
NAGANEO Rie
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan Inc.
-
SUGIMOTO Hiromi
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan Inc.
関連論文
- Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A
- Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model
- Contribution of Active and Inactive States of the Human 5-HT_ Receptor to the Functional Activities of 5-HT_4-Receptor Agonists
- Pharmacological Evaluation of a Novel Cannabinoid 2 (CB_2) Ligand, PF-03550096, In Vitro and In Vivo by Using a Rat Model of Visceral Hypersensitivity
- Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against .ALPHA.-Fas-Induced Liver Injury in a Mouse Model